BTK and skin neoplasm: Studies in glioblastoma and skin cancer found that Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib induced protective autophagy, and inhibition of autophagy could increase the efficacy of ibrutinib [24, 25].